What is Claimed is:

1. A composition comprising a pharmaceutically acceptable cyclobenzaprine salt and a basifying agent, characterized in that, when the composition is administered by transmucosal absorption, the composition affords a cyclobenzaprine dnC* of: greater than or equal to 0.1 ± 25% x 10^{-7} mL^{-1} 15 minutes after administration; greater than or equal to 0.5 ± 25% x 10^{-7} mL^{-1} 30 minutes after administration; greater than or equal to 1.5 ± 25% x 10^{-7} mL^{-1} 45 minutes after administration; greater than or equal to 4.0 ± 25% x 10^{-7} mL^{-1} 1 hour after administration; greater than or equal to 5.2 ± 25% x 10^{-7} mL^{-1} 2 hours after administration; greater than or equal to 9.0 ± 25% x 10^{-6} mL^{-1} 3 hours after administration; and/or less than or equal to 5.0 ± 25% x 10^{-7} mL^{-1} 10 hours, 12 hours, 14, hours, 16 hours or 18 hours after administration.

2. The composition of claim 1, wherein the transmucosal absorption is sublingual absorption.

3. The composition of claim 1 or 2, wherein the basifying agent is selected from the group consisting of potassium dihydrogen phosphate, dipotassium hydrogen phosphate, tripotassium phosphate, sodium carbonate, sodium bicarbonate, calcium carbonate, calcium bicarbonate, TRIS buffer, sodium dihydrogen phosphate, disodium hydrogen phosphate, trisodium phosphate, potassium carbonate, potassium bicarbonate, potassium acetate, sodium acetate, dipotassium citrate, tripotassium citrate, disodium citrate and trisodium citrate.

4. The composition of any one of claims 1 to 3, characterized in that the composition affords a cyclobenzaprine dnC* of greater than or equal to 1.0 ± 25% x 10^{-7} mL^{-1} 20 minutes after administration; greater than or equal to 157.60 x 10^{-9} mL^{-1} 20 minutes after administration; greater than or equal to 2.5 ± 25% x 10^{-7} mL^{-1} 30 minutes after administration; greater than or equal to 3.0 ± 25% x 10^{-7} mL^{-1} 45 minutes after administration; 4.2 ± 25% x 10^{-7} mL^{-1} 60 minutes after administration; greater than or equal to 6.0 ± 25% x 10^{-7} mL^{-1} 2 hours after administration; greater than or

equal to 6.5 ± 25% x 10^{-7} mL^{-1} 2.5 hours after administration; or greater than or equal to 7.0 ± 25% x 10^{-7} mL^{-1} 3 hours after administration.

5. The composition of any one of claims 1 to 4, characterized in that the cyclobenzaprine has a $dnAUC_{0\text{-}20min}$ of greater than or equal to 0.02 ± 25% x 10^{-6} hr mL^{-1}, a $dnAUC_{0\text{-}30min}$ of greater than or equal to 0.05 ± 25% x 10^{-6} hr mL^{-1}, a $dnAUC_{0\text{-}45min}$ of greater than or equal to 0.14 ± 25% x 10^{-6} hr mL^{-1}, a $dnAUC_{0\text{-}1h}$ of greater than or equal to 0.26 ± 25% x 10^{-6} hr mL^{-1}, a $dnAUC_{0\text{-}2h}$ of greater than or equal to 0.87 ± 25% x 10^{-6} hr mL^{-1}, or a $dnAUC_{0\text{-}2.5h}$ of greater than or equal to 1.23 ± 25% x 10^{-6} hr mL^{-1}.

6. The composition of any one of claims 1 to 5, characterized in that the cyclobenzaprine has a $dnAUC_{0\text{-}\infty h}$ of greater than or equal to 20 hr mL^{-1}.

7. The composition of any one of claims 1 to 6, characterized in that the cyclobenzaprine has a dnC_{max}* of greater than or equal to 1.0 ± 25% x 10^{-6} mL^{-1}.

8. The composition of any one of claims 1 to 7, characterized in that the cyclobenzaprine has a plasma concentration of 50% or less of the C_{max} 4 hours, 6 hours, 8 hours and/or 12 hours after administration.

9. The composition of any one of claims 1 to 8, characterized in that the cyclobenzaprine has a C_{max} of greater than or equal to 2 ng/mL, 10 ng/mL, 15 ng/mL, 20 ng/mL, 25 ng/mL, or 30 ng/mL.

10. The composition of any one of claims 1 to 9, characterized in that the cyclobenzaprine has a C_{max} of greater than or equal to 2 ng/mL, 10 ng/mL, 15 ng/mL, 20 ng/mL, 25 ng/mL or 30 ng/mL above the baseline level of cyclobenzaprine in the individual immediately prior to administration.

11. The composition of any one of claims 1 to 10, characterized in that the cyclobenzaprine has a t_{max} of of less than 4 hours, less than 3 hours, less than 2 hours, less than 1 hour, less than 45 minutes, less than 30 minutes, or less than 15 minutes.

12. The composition of any one of claims 1 to 3 comprising about 2 to about 20 mg of a pharmaceutically acceptable cyclobenzaprine salt, said composition affording a C_{max} of cyclobenzaprine from 20 ng/mL to 200 ng/mL from 0.05 to 2.5 hours after administration, and a minimum cyclobenzaprine plasma concentration from 1 ng/mL to 5 ng/mL from 22 hours to 26 hours after administration, wherein the composition is administered for four days or more of daily administration.

13. Use of a composition according to any one of claims 1 to 12 in the manufacture of a medicament for transmucosal absorption for treating a disease or condition in an individual, wherein the disease or condition is selected from the group consisting of post-traumatic stress disorder (PTSD), fibromyalgia, depression, traumatic brain injury, sleep disorder, non-restorative sleep, chronic pain, muscle spasm, and anxiety disorder.

14. The use according to claim 13, wherein the transmucosal absorption is sublingual absorption, optionally wherein the medicament is selected from the group consisting of a sublingual tablet, a sublingual film, a sublingual powder, and a sublingual spray solution.

15. The use according to claim 13 or 14, wherein the disease or condition is post-traumatic stress disorder (PTSD)

16. The use according to claim 13 or 14, wherein the disease or condition is selected from the group consisting of fibromyalgia, depression, traumatic brain injury, sleep disorder, non-restorative sleep, chronic pain, muscle spasm, and anxiety disorder.

17. The use according to any one of claims 13 to 16, wherein the medicament affords a cyclobenzaprine dnC* of greater than or equal to $1.0 \pm 25\% \times 10^{-7}$ mL^{-1} 20 minutes after administration; greater than or equal to $2.5 \pm 25\% \times 10^{-7}$ mL^{-1} 30 minutes after administration; greater than or equal to $3.0 \pm 25\% \times 10^{-7}$ mL^{-1} 45 minutes after administration; greater than or equal to $4.2 \pm 25\% \times 10^{-7}$ mL^{-1} 1 hour after administration; greater than or equal to $6.0 \pm 25\% \times 10^{-7}$ mL^{-1} 2 hours after administration; greater than or equal to $7.0 \pm 25\% \times 10^{-7}$ mL^{-1} 3 hours after administration; greater than or equal to $8.0 \pm 25\% \times 10^{-7}$ mL^{-1} 3.3 hours after

administration; and/or less than or equal to 5.0 ± 25% x 10^{-7} mL^{-1} 12 hours, 14 hours, 16 hours and/or 18 hours after administration.

18. The use according to any one of claims 13 to 17, wherein the cyclobenzaprine has a dnC* of greater than or equal to 1.0 ± 25% x 10^{-7} mL^{-1} 20 minutes after administration; greater than or equal to 2.5 ± 25% x 10^{-7} mL^{-1} 30 minutes after administration; greater than or equal to 3.0 ± 25% x 10^{-7} mL^{-1} 45 minutes after administration; greater than or equal to 4.2 ± 25% x 10^{-7} mL^{-1} 1 hour after administration; greater than or equal to 6.0 ± 25% x 10^{-7} mL^{-1} 2 hours after administration; greater than or equal to 6.5 ± 25% x 10^{-7} mL^{-1} 2.5 hours after administration; greater than or equal to 727.67 ± 25% x 10^{-9} mL^{-1} 2.5 hours after administration; or greater than or equal to 7.0 ± 25% x 10^{-7} mL^{-1} 3 hours after administration.

19. Use of a composition according to any one of claims 1 to 3 in the manufacture of a medicament for reducing the symptoms of fibromyalgia in a human patient, wherein when a transmucosal dosage of the medicament comprising from 2 mg to 20 mg of a pharmaceutically acceptable cyclobenzaprine salt is administered, said medicament affords a C_{max} of cyclobenzaprine from 20 ng/mL to 200 ng/mL from 0.05 hours to 2.5 hours after administration, and a minimum plasma concentration from 1 ng/mL to 5 ng/mL from 22 hours to 26 hours after administration, wherein the medicament is administered for four days or more of daily administration, and wherein the medicament is administered within two hours of sleep.